The company stated that on February 18, 2026, it entered into a definitive agreement with MPGL to acquire the India rights for these trademarks and associated assets for USD 32.15 million.
According to the announcement, this acquisition is domestic in scope and will strengthen Dr. Reddy’s gynecology portfolio in India, marking the company’s entry into the Hormone Replacement Therapy (HRT) segment. MPGL is not a related party, and the deal has been executed at arm’s length.
This acquisition is expected to significantly bolster Dr. Reddy’s presence in the Hormone Replacement Therapy (HRT) segment and further strengthen its gynecology portfolio in the Indian market. By securing these specialty brands, the company aims to expand its offerings and reinforce its position in the women’s health segment.
On Wednesday, Dr. Reddy’s shares closed slightly lower at Rs 1,280.30, down 0.36% on the NSE. The stock currently trades at a PE ratio of 19.19 and a PB ratio of 3.15, suggesting moderate valuation levels relative to its fundamentals.
From a technical perspective, Dr. Reddy’s Laboratories shows a 14-day RSI of 60.4, indicating a neutral to slightly bullish momentum, with readings above 70 considered overbought and below 30 oversold. The stock is also trading above all eight key simple moving averages (SMAs), reflecting a strong bullish trend.
In the December 2025 quarter, foreign portfolio investors (FPIs) reduced their holdings in Dr. Reddy’s Laboratories from 24.69% to 22.34%, while mutual funds increased their stake from 13.31% to 13.87%.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)